Loading viewer...
investor_presentation
Format: PDF investor_presentation
CTI BioPharma presented its hematology-focused pipeline at an investor conference, highlighting clinical programs including pacritinib for myelofibrosis, PIXUVRI for non-Hodgkin lymphoma, and tosedostat for acute myeloid leukemia. The presentation outlines the company's development strategy and regulatory pathway across Phase 2 and Phase 3 programs.
presentation
investor_presentation
14 Pages
Vishay Precision Group
Constellation Pharmaceuticals Investor Presentation — January 2020
investor_presentationinvestor_presentation
48 Pages
Constellation Pharmaceuticals